ASBM Files Comments to the FTC
March 1, 2014
The Alliance for Safe Biologic Medicines submitted comments to the Federal Trade Commission in regards to the “Follow-On Biosimilars Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition” hearing held in February. Read comments here.